buspirone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anxiolytics, buspirone derivatives 437 36505-84-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buspirone
  • buspin
  • buspirone hydrochloride
  • buspirone HCl
An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
  • Molecular weight: 385.51
  • Formula: C21H31N5O2
  • CLOGP: 2.19
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 0
  • TPSA: 69.64
  • ALOGS: -2.82
  • ROTB: 6

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.59 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 3.90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Sept. 29, 1986 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1762.71 76.01 342 429 20692 2336622
Toxicity to various agents 678.31 76.01 174 597 32580 2324734
Cardio-respiratory arrest 191.94 76.01 50 721 9096 2348218
Respiratory arrest 185.42 76.01 45 726 6133 2351181
Overdose 178.40 76.01 56 715 19851 2337463
Poisoning 156.91 76.01 34 737 2786 2354528
Cardiac arrest 154.66 76.01 47 724 14883 2342431
Hypothermia 131.28 76.01 28 743 2120 2355194
Serotonin syndrome 101.92 76.01 25 746 3515 2353799
Rhabdomyolysis 99.61 76.01 28 743 6676 2350638
Intentional overdose 85.14 76.01 28 743 11293 2346021
Neuroleptic malignant syndrome 76.93 76.01 18 753 2062 2355252

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 504.36 51.06 116 295 16196 1730174
Toxicity to various agents 186.58 51.06 61 350 29080 1717290
Electrocardiogram QRS complex prolonged 116.60 51.06 21 390 754 1745616
Anxiety 92.20 51.06 31 380 15496 1730874
Serotonin syndrome 84.52 51.06 20 391 2768 1743602
Drug abuse 83.84 51.06 28 383 13661 1732709
Cardiogenic shock 81.71 51.06 19 392 2435 1743935
Respiratory arrest 78.96 51.06 22 389 5817 1740553
Intentional overdose 73.03 51.06 22 389 7648 1738722
Cardiac arrest 68.28 51.06 25 386 15905 1730465
Muscle necrosis 68.18 51.06 11 400 199 1746171
Bradycardia 62.17 51.06 21 390 10513 1735857
Seizure 58.75 51.06 24 387 20417 1725953
Cardio-respiratory arrest 56.67 51.06 19 392 9274 1737096
Agitation 53.49 51.06 19 392 11007 1735363

Pharmacologic Action:

SourceCodeDescription
ATC N05BE01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Azaspirodecanedione derivatives
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:35717 sedative
CHEBI has role CHEBI:35474 anxiolytic drug
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Generalized anxiety disorder indication 21897009 DOID:14320
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.51 Basic
pKa2 2.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST EC50 7.25 WOMBAT-PK CHEMBL
D(4) dopamine receptor GPCR Ki 7 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.28 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 7.68 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 6.44 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.04 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 6.41 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 6.60 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 5.13 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.40 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.92 CHEMBL
D(3) dopamine receptor GPCR Ki 6.18 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 4.34 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 5.77 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.32 WOMBAT-PK
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 5.47 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.32 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.21 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 6.86 CHEMBL
D(2) dopamine receptor GPCR Ki 7.36 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 6.76 CHEMBL
Dopamine receptor GPCR IC50 6.92 CHEMBL
Adrenergic receptor alpha-2 GPCR IC50 5 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 4.80 CHEMBL
Alpha-2A adrenergic receptor GPCR IC50 5 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR IC50 7.02 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.77 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 8.42 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.75 CHEMBL
D(2) dopamine receptor GPCR Ki 6.92 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 6 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 6.32 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 6.40 IUPHAR
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 6.40 IUPHAR

External reference:

IDSource
D002065 MESH_DESCRIPTOR_UI
4019646 VUID
N0000147739 NUI
C0006462 UMLSCUI
D00702 KEGG_DRUG
207LT9J9OC UNII
33386-08-2 SECONDARY_CAS_RN
91452003 SNOMEDCT_US
4019646 VANDF
1827 RXNORM
387523009 SNOMEDCT_US
d00182 MMSL
004586 NDDF
CHEMBL49 ChEMBL_ID
DB00490 DRUGBANK_ID
CHEMBL1200399 ChEMBL_ID
3456 INN_ID
CHEBI:3223 CHEBI
36 IUPHAR_LIGAND_ID
2477 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0053 TABLET 5 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-0054 TABLET 10 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-1003 TABLET 15 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0093-5200 TABLET 30 mg ORAL ANDA 14 sections
Buspirone HCl HUMAN PRESCRIPTION DRUG LABEL 1 0115-1690 TABLET 5 mg ORAL ANDA 14 sections
Buspirone HCl HUMAN PRESCRIPTION DRUG LABEL 1 0115-1691 TABLET 10 mg ORAL ANDA 14 sections
Buspirone HCl HUMAN PRESCRIPTION DRUG LABEL 1 0115-1692 TABLET 15 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1140 TABLET 5 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1145 TABLET 7.50 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1150 TABLET 10 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1165 TABLET 15 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1175 TABLET 30 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4575 TABLET 10 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4595 TABLET 5 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-4596 TABLET 15 mg ORAL ANDA 15 sections
BusPIRone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-5548 TABLET 7.50 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7633 TABLET 5 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7634 TABLET 10 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7635 TABLET 15 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7689 TABLET 15 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7714 TABLET 5 mg ORAL ANDA 15 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7718 TABLET 10 mg ORAL ANDA 15 sections
Buspirone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6899 TABLET 15 mg ORAL ANDA 14 sections
Buspirone HCl HUMAN PRESCRIPTION DRUG LABEL 1 10544-176 TABLET 10 mg ORAL ANDA 14 sections
BUSPIRONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-375 TABLET 30 mg ORAL ANDA 15 sections
BUSPIRONE HCl HUMAN PRESCRIPTION DRUG LABEL 1 16590-579 TABLET 15 mg ORAL ANDA 13 sections
BUSPIRONE HUMAN PRESCRIPTION DRUG LABEL 1 16590-600 TABLET 10 mg ORAL ANDA 13 sections
BUSPIRONE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-727 TABLET 7.50 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-200 TABLET 5 mg ORAL ANDA 14 sections
Buspirone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-201 TABLET 7.50 mg ORAL ANDA 14 sections